Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the absolute bioavailability of a
single, fixed sub-cutaneous (SC) dose of aducanumab compared with a single, weight-based
intra-venous (IV) dose in healthy participants and to characterize the pharmacokinetics (PK)
profile of aducanumab. The secondary objectives are to evaluate the safety and tolerability
of aducanumab administered via SC and IV routes in healthy participants and to characterize
additional PK parameters of a single, fixed SC dose of aducanumab and a weight-based IV dose
in healthy participants.